• 1
    van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251337.
  • 2
    Tessier-Lavigne M. Eph receptor tyrosine kinases, axon repulsion, and the development of topographic maps. Cell 1995; 82: 3458.
  • 3
    Inslow JW, Moran P, Valverde J, Shih A, Yuan JQ, Wong SC, Tsai SP, Goddard A, Henzel WJ, Hefti F, et al. Cloning of AL-1, a ligand for an Ephrelated tyrosine kinase receptor involved in axon bundle formation. Neuron 1995; 14: 97381.
  • 4
    Wang HU, Anderson DJ. Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron 1997; 18: 38396.
  • 5
    Lumsden A, Krumlauf R. Patterning the vertebrate neuraxis. Science 1996; 274: 110915.
  • 6
    Magal E, Holash JA, Toso RJ, Chang D, Lindberg RA, Pasquale EB. B61, a ligand for the Eck receptor protein-tyrosine kinase, exhibits neurotrophic activity in cultures of rat spinal cord neurons. J Neurosci Res 1996; 43: 73544.
  • 7
    Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF- alpha-induced angiogenesis. Science 1995; 268: 5679.
  • 8
    Maru Y, Hirai H, Yoshida MC, Takaku F. Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol Cell Biol 1988; 8: 37706.
  • 9
    Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61: 23016.
  • 10
    Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000; 19: 604352.
  • 11
    Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otsuki Y, Kobayashi T, Konno H, Hanai H, Sugimura H. Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 2002; 128: 3438.
  • 12
    Straume O, Akslen LA. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2002; 160: 100919.
  • 13
    Igarashi H, Sugimura H, Maruyama K, Kitayama Y, Ohta I, Suzuki M, Tanaka M, Dobashi Y, Kino I. Alteration of immunoreactivity by hydrated autoclaving, microwave treatment, and simple heating of paraffin-embedded tissue sections. APMIS 1994; 102: 295307.
  • 14
    Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, de Laurentiis M, de Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 8816.
  • 15
    Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 76570.
  • 16
    Tsuji T, Sasaki Y, Tanaka M, Hanabata N, Hada R, Munakata A. Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis. Lab Invest 2002; 82: 55562.
  • 17
    Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9: 38391.
  • 18
    Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995; 60: 12936.
  • 19
    Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999; 41: 27580.
  • 20
    Artley TD, Hunt RW, Welcher AA, Boyle WJ, Parker VP, Lindberg RA, Lu HS, Colombero AM, Elliott RL, Guthrie BA, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994; 368: 55860.
  • 21
    Holzman LB, Marks RM, Dixit VM. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol CellBiol 1990; 10: 58308.
  • 22
    Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999; 84: 494501.
  • 23
    Rosenberg IM, Goke M, Kanai M, Reinecker HC, Podolsky DK. Epithelial cell kinase—B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997; 273: G82432.
  • 24
    Potla L, Boghaert ER, Armellino D, Frost P, Damle NK. Reduced expression of EphrinA1 (EFNA1) inhibits three—dimensional growth of HT29 colon carcinoma cells. Cancer Lett 2002; 175: 18795.
  • 25
    Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node—negative colon cancer. Ann Surg 1995; 222: 6959.
  • 26
    Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132: 5416.
  • 27
    Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 22631.
  • 28
    Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 10436.
  • 29
    Cheng N, Chen J. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem 2001; 276: 137717.
  • 30
    Carter N, Nakamoto T, Hirai H, Hunter T. EphrinA1-induced cytoskeletal reorganization requires FAK and p130(cas). Nat Cell Biol 2002; 4: 56573.
  • 31
    Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 701126.
  • 32
    Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002; 62: 28407.
  • 33
    Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002; 1: 211.
  • 34
    Wang Y, Ota S, Kataoka H, Kanamori M, Li Z, Band H, Tanaka M, Sugimura H. Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun 2002; 296: 21420.